CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
clozapine +1 moredrug
Likely dose
clozapine 450mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00573287
NCT00573287N/ACompleted

Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder

Dartmouth-Hitchcock Medical Center·interventional·Posted Dec 14, 2007·Updated Jul 23, 2019

In Brief

A clinical study evaluating clozapine and risperidone for Cannabis-Related Disorder and 3 related conditions. Completed, enrolled 14 participants across 5 sites.

Detailed Summary

Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response. Preliminary evidence suggests that clozapine may uniquely reduce substance use in patients with schizophrenia. The purpose of this study is to establish an effective methodology for studying early treatment with clozapine in patients with co-occurring schizophrenia and cannabis use disorder, while generating pilot data comparing clozapine vs. risperidone on substance use, psychiatric symptoms, side effects, and treatment discontinuation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 14, 2007
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2010
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 18.6 years ago

Interventions

clozapinedrug

clozapine--tabs, 450mg. max, daily, 24 weeks

risperidonedrug

risperidone--tabs, 6mg max, daily, 24 weeks